

## Hemovigilance Module Adverse Reaction Delayed Serologic Transfusion Reaction

*Required for saving	
*Facility ID#: NF	ISN Adverse Reaction #:
Patient Information	
*Patient ID: Social Security #: Last Name:	Secondary ID: Medicare #:
Ethnicity Hispanic or Lati	ino 🛛 Not Hispanic or Not Latino
Race American Indian C Native Hawaiia *Blood Group: A- A+ Transitional /	n/Alaska Native Asian Black or African American n/Other Pacific Islander White B- B- B+ AB- AB+ O- O+ Blood type not done ABO / Rh + Transitional ABO / Rh - Transitional ABO / Transitional Rh Group B/Transitional Rh Group O/Transitional Rh
Patient Medical History	
	Jiagnosis. (Use ICD-10 Diagnostic codes/descriptions)
Code:	Description:
Code:	Description:
Code:	Description:
List the patient's underlying	indication for transfusion. (Use ICD-10 Diagnostic codes/descriptions)
Code:	Description:
Code:	Description:
Code:	Description:
List the patient's comorbid or reaction. (Use ICD-10 Diag	conditions at the time of the transfusion related to the adverse
Code:	Description:
Code:	Description:
Code:	Description:
any individual or institution is collect and will not otherwise be disclosed	oluntarily provided information obtained in this surveillance system that would permit identification of ted with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, or released without the consent of the individual, or the institution in accordance with Sections 304, Service Act (42 USC 242b, 242k, and 242m(d)).
reviewing instructions, searching ex collection of information. An agency	ction of information is estimated to average 20 minutes per response, including the time for isting data sources, gathering and maintaining the data needed, and completing and reviewing the y may not conduct or sponsor, and a person is not required to respond to a collection of information MB control number. Send comments regarding this burden estimate or any other aspect of this

unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333 ATTN: PRA (0920-0666).



	's relevant medical procedure including past procedures and procedures to be ng the current hospital or outpatient stay. (Use ICD-10 Procedure ions)					
Code:	Description: _					
Code:	Description: _					
Code:	Description: _					
Additional Information						
Transfusion History						
Date of Transfusion:	VB 🗌 RBC 🗌 Pla	] UNKNOWN				
	about the transfusion a e reaction:	dverse reaction.	NO DSTR			
Reaction Details						
*Date reaction occurred:/ *Time reaction occurred:: Time unknown *Facility location where patient was transfused: Is this reaction associated with an incident?YesNoIf Yes, Incident #:						
Investigation Results						
* Delayed serologic tran Antibody(ies):	•	•				
<ul> <li>*Case Definition Check all that apply:</li> <li>Absence of clinical signs of hemolysis</li> <li>Positive direct antiglobulin test (DAT)</li> <li>Demonstration of new, clinically-significant antibodies against red blood cells</li> <li>Positive antibody screen with newly identified RBC alloantibody</li> </ul>						
Other signs and symptoms:	(check all that apply)					
Generalized:	Chills/rigors	Fever	] Nausea/vomiting			
Cardiovascular:	Blood pressure de	ecrease Shock				
Cutaneous:	Edema Other rash	Flushing Flushing Pruritus (itching)	] Jaundice ] Urticaria (hives)			
Hemolysis/Hemorrhage:	Disseminated intra	avascular coagulation 🛛 Hemoglob	inemia			
Pain:	Abdominal pain	🗌 Back pain 🔄 Flank pain	Infusion site pain			
Renal:	🗌 Hematuria	🗌 Hemoglobinuria 📃	] Oliguria			
Respiratory:	Bilateral infiltrates on chest x-ray       Bronchospasm       Cough         Hypoxemia       Shortness of breath					
Other: (specify)						

N-ISN National Healthcare Safety Network	Form Approved OMB No. 0920-0666 Exp. Date: 12/31/22 www.cdc.gov/nhsn				
*Severity					
Since this is by definition a reaction with no clinical symptoms, severity of the reaction ca	innot be graded.				
⊠ Not determined	-				
*Imputability					
Which best describes the relationship between the transfusion and the reaction?					
<ul> <li>Transfusion performed by your facility is the only possible cause for seroconversion.</li> <li>The patient has other exposures (e.g. transfusion by another facility or pregnancy) that could explain seroconversion, but transfusion by your facility is the most likely cause.</li> <li>The patient was transfused by your facility, but other exposures are present that most likely explain seroconversion.</li> </ul>					
Evidence is clearly in favor of a cause other than the transfusion, but transfusion ca	innot be excluded.				
There is conclusive evidence beyond reasonable doubt of a cause other than the tra	ansfusion.				
The relationship between the adverse reaction and the transfusion is unknown or not stated.					
Did the transfusion occur at your facility?					
<ul> <li>When was the new alloantibody identified?</li> <li>Occurred between 24 hours and 28 days after cessation of transfusion</li> <li>Occurred less than 24 hours after cessation of transfusion OR greater than 28 days after cessation of transfusion</li> <li>No new antibody was identified</li> </ul>					
Module-generated Designations					
NOTE: Designations for case definition, severity, and imputability will be automatically assigned application based on responses in the corresponding investigation results section above.	ed in the NHSN				
*Do you agree with the case definition designation?          YES          *Please indicate your designation	□ NO				
*Do you agree with the severity designation?          YES          *Please indicate your designation	□ NO				
*Do you agree with the <i>imputability</i> designation?	NO				
Patient Treatment					
Did the patient receive treatment for the transfusion reaction?       YES       NO         If yes, select treatment(s):       Medication (Select the type of medication)					
<ul> <li>Antipyretics</li> <li>Antihistamines</li> <li>Inotropes/Vasopressors</li> <li>Bronchodil</li> <li>Intravenous Immunoglobulin</li> <li>Intravenous steroids</li> <li>Corticosteroids</li> <li>Antithymocyte globulin</li> <li>Cyclosporin</li> <li>Other</li> </ul>	ator Diuretics				
Volume resuscitation (Intravenous colloids or crystalloids)					
Respiratory support <i>(Select the type of support)</i> Mechanical ventilation Noninvasive ventilation Oxygen					
Renal replacement therapy (Select the type of therapy)					
Hemodialysis Peritoneal CDC 57.310 Rev.2, v9.2	1				

NHSN National Healthc Safety Netwo	Are ork					OMB No. ( Exp. Date	Approved 0920-0666 e: 12/31/22 c.gov/nhsn				
Phlebotomy											
☐ Other Specify:											
Outcome											
*Outcome: Death Major or long-term sequelae Minor or no sequelae Not determined											
	Date of Death://										
	recipient died, relation Definite	•		Ruled Out	🗌 Not do	termine	Ч				
	of death:					termine	u				
	autopsy performed?	🗌 Yes	No								
Component Details         *Was a particular unit implicated in (i.e., responsible for) the adverse         reaction?											
Transfusion Start and <b>End</b> Date/Time	*Component code (check system used)	Amount transfused at reaction onset	<sup>•</sup> Unit number (Required for Infection and TRALI)	*Unit expiration Date/Time	*Blood group a		Implic ated Unit?				
^IMPLICATED							•				
	□ ISBT-128										
:	☐ Codabar	Entire unit		/ /	□ A- □ A+ [	🗆 В-	N				
		Partial unitmL			□в+ □ Ав-	AB+	Y				
:				:		 □ N/A					
//	□ ISBT-128										
:	☐ Codabar	Entire unit Partial unit		//	□ A- □ A+ [	□ B-	NI				
//		mL			□в+ □ Ав- [	AB+	Ν				
:::				:	□0- □0+	□ N/A					
Custom Field	ds				· · · · ·						
Label			Label								
		//			/	_/					
Comments											

